MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin

Conditions

Rituximab — DRUG
weekly administration of Rituximab 375mg/m2 during cycle 1 and 2, monthly administration from cycle 3(up to cycle 6)
Fludarabine — DRUG
administration of fludarabine 20mg/m2 for 3 consecutive days starting at 3 days before the 1st, 3rd, and 5th cycle of the first rituximab infusion for that cycle
Cyclophosphamide — DRUG
administration of fludarabine 250mg/m2 for 3 consecutive days starting at 3 days before the 1st, 3rd, and 5th cycle of the first rituximab infusion for that cycle
MG4101(allogeneic Natural Killer cell) — BIOLOGICAL
administration every fortnight for each cycle, beginning with the 1st dose of rituximab for that cycle.
Interleukin-2 — DRUG
1 x 10\^6 IU/m2, together with MG4101

To determine the efficacy and safety of combined therapy of determined MG4101 dose and Rituximab.

Experimental: single arm
1. Phase 1 1. MG4101 (Allogeneic Natural Killer cell): i.v bi-weekly * Group 1: 1 x 10\^7 cells/㎏ * Group 2: 3 x 10\^7 cells/㎏ * Group 3: 9 x 10\^7 cells/㎏ 2. Interleukin-2 (IL-2): s.c bi-weekly with MG4101 at 1X10\^6 IU/m2 per day. 3. Rituximab: 375mg/m2. i.v. weekly for the first 2 cycles only (8 doses). monthly (3-6 cycle) 4. Lymphodepletion: Fludarabine 20mg/m2 + Cyclophosphamide 250 mg/m2 i.v. D-3, D-2, D-1 of 1st, 3rd, and 5th cycle 2. Phase 2a Administration of recommended dosage of MG4101 determined from Phase 1 will be applied in Phase 2a. Dosage regimens for lymphodepletion, IL-2 and Rituximab will be the same as Phase 1.

Phase I - Maximum Tolerated Dose of the dose of MG4101 in combination with Rituximab [ Time Frame: 28 days ]